Najay Cummings v. James Cassar, In Individual and Official Capacity, and Chelsea Whittaker

CourtDistrict Court, S.D. New York
DecidedDecember 11, 2025
Docket1:23-cv-11184
StatusUnknown

This text of Najay Cummings v. James Cassar, In Individual and Official Capacity, and Chelsea Whittaker (Najay Cummings v. James Cassar, In Individual and Official Capacity, and Chelsea Whittaker) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Najay Cummings v. James Cassar, In Individual and Official Capacity, and Chelsea Whittaker, (S.D.N.Y. 2025).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK NAJAY CUMMINGS, Plaintiff, 23 Civ. 11184 (KPF) -v.- OPINION AND ORDER JAMES CASSAR, In Individual and Official Capacity, and CHELSEA WHITTAKER,

Defendants. KATHERINE POLK FAILLA, District Judge: Defendants James Cassar and Chelsea Whittaker (collectively, “Defendants”) were health care providers who prescribed and administered Zoloft to Plaintiff Najay Cummings while he was detained at Rikers Island for several months in 2019. Mr. Cummings alleges that the medication caused him various health issues, including hyperprolactinemia, gynecomastia, and a sustained loss of libido. He brought this action pro se against Defendants alleging a violation of his constitutional rights under 42 U.S.C. § 1983. Before the Court now is Defendants’ motion to dismiss.

For the reasons set forth below, the Court grants Defendants’ motion to dismiss. In short, the Court does not doubt the difficulties Mr. Cummings’s proffered medical issues have caused. But Mr. Cummings’s claims nevertheless fail because he has not alleged conduct by Defendants that gives rise to a Section 1983 violation. BACKGROUND1 A. Factual Background At some point during or before May 2019, Mr. Cummings was placed in the custody of the New York City Department of Correction (“DOC”) at Rikers Island. (AC 5). After his detention, Mr. Cummings’s suicidal ideations began

increasing in frequency. (Id.). In response, Rikers Island medical staff performed a mental health evaluation (id.), and subsequently placed Mr. Cummings on what he terms a “suicide watch” (Nov. 8 Letter 1). After the evaluation, Mr. Cummings’s medical provider, Mr. Cassar, a psychiatric nurse practitioner with Correctional Health Services (Dkt. #10), recommended that Mr. Cummings take medication to help with his depression and suicidal ideations (AC 5). Mr. Cummings agreed, and Mr. Cassar later prescribed Zoloft. (Id. at 5-6; PMC Tr. 7:24-8:25).

1 This Opinion draws its facts from the Amended Complaint (“AC” (Dkt. #25)), the well- pleaded allegations of which are taken as true for purposes of this Opinion. See Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). In addition, because this is a pro se matter, the Court considers the facts that Plaintiff asserted (i) in a November 8, 2025 pre- motion letter (“Nov. 8 Letter” (Dkt. #41)); (ii) at the January 17, 2025 pre-motion conference (“PMC Tr.” (Dkt. #46)); (iii) in a February 13, 2025 letter (“Feb. 13 Letter” (Dkt. #47)); and (iv) in exhibits attached to a Declaration he provided with his opposition brief (“Cummings Decl.” (Dkt. #55)). See Yates v. Villalobos, No. 15 Civ. 8068 (KPF), 2018 WL 718414, at *1 n.2 (S.D.N.Y. Feb. 5, 2018) (“Courts may also consider statements made in response to a defendant’s request for a pre-motion conference and statements made during that conference.” (collecting cases)); Alsaifullah v. Furco, No. 12 Civ. 2907 (ER), 2013 WL 3972514, at *4 n.3 (S.D.N.Y. Aug. 2, 2013) (explaining that courts may consider factual assertions a pro se plaintiff makes in a wide variety of sources). (See also Dkt. #43 at 1 (noting that the Court would deem the AC “to have been amended to include those factual assertions … made by Plaintiff during the [pre-motion] conference” and collecting cases in support)). For ease of reference, the Court refers to Defendants’ memorandum of law in support of their motion to dismiss as “Def. Br.” (Dkt. #48-13); to Plaintiff’s memorandum of law in opposition to Defendants’ motion to dismiss as “Pl. Opp.” (Dkt. #54); and to Defendants’ reply memorandum of law as “Def. Reply” (Dkt #56). As a final note, when referring to Plaintiff’s submissions, this Opinion refers to the page numbers assigned by the Court’s Electronic Case Filing (“ECF”) system. Mr. Cummings alleges that during his conversations with Mr. Cassar about Zoloft, Mr. Cassar failed to inform him about certain side effects of Zoloft. (AC 7). Mr. Cassar allegedly informed Mr. Cummings about the

possibility of increased suicidal ideations, nausea, and vomiting, but not the possibility of decreased libido or gynecomastia. (Id. at 8; PMC Tr. 9:1-9:15).2 Furthermore, Mr. Cassar allegedly did not share any documents with Mr. Cummings regarding Zoloft’s possible side effects and did not tell Mr. Cummings to read Zoloft’s medication guide. (AC 7; PMC Tr. 9:16-9:20). Mr. Cummings asserts that not knowing all of Zoloft’s side effects kept him from “properly and effectively weigh[ing] Zoloft’s risks against its benefits.” (AC 7). Had Mr. Cummings have known of the potential for decreased libido, which he

alleges is “a common side effect” of Zoloft, he suggests that he would have refused the drug as a treatment option. (Id. at 7-8). Instead, Mr. Cummings took Zoloft daily, which Ms. Whittaker, a pharmacy technician with Physician Affiliate Group of New York, Inc. (Dkt. #10), administered to him, also without mentioning any possible side effects (AC 8; PMC Tr. 10:1-11:3). Mr. Cummings missed only the occasional dose. (PMC Tr. 11:6-11:20). He took Zoloft from sometime after May 2019 to the first quarter of 2020. (Id. at 7:14-7:23, 10:1-10:7).

In late October 2019, during the course of his Zoloft treatment, Mr. Cummings was transferred to state custody. (PMC Tr 28:8-28:20). At some

2 Gynecomastia is enlarged breast tissue in males often caused by a hormone imbalance. Gynecomastia, Clev. Clinic, https://my.clevelandclinic.org/health/symptoms/16227- enlarged-male-breast-tissue-gynecomastia (last visited Dec. 1, 2025). point after being transferred to a state facility, Mr. Cummings had a discussion with a medical provider, after which he stopped taking Zoloft. (AC 6; PMC Tr. 13:7-13:22, 19:15-19:23, 30:7-30:19). He did so because he felt that the

drug “wasn’t helping” him. (PMC Tr. 12:24-13:5). In fact, according to Mr. Cummings, Zoloft allegedly increased his suicidal ideations, decreased his libido, and caused him difficulty maintaining an erection. (PMC Tr. 15:14-17:16, 26:5-26:10). But Mr. Cummings initially did not speak with any medical service provider about these side effects because he had no reason to believe that they were due to taking Zoloft. (Id. at 17:24-18:23). Between November 14, 2019, and December 13, 2019, Mr. Cummings briefly took a different mental health medication, Remeron.

(Feb. 13 Letter 1-2). In September 2020, after Mr. Cummings had stopped taking both Zoloft and Remeron, he first noticed “a difference around [his] nipple area.” (Feb. 13 Letter 1). That change became “aggressive” in 2022 and 2023, with Mr. Cummings noticing a gradual growth in his nipples. (Id.; AC 6-7). At that point, Mr. Cummings sought the attention of the prison’s health care providers. (AC 6-7). Blood tests revealed high levels of prolactin (hyperprolactinemia), a hormone that stimulates breast development and milk production. (Id. at 6).

In October 2023, Mr. Cummings consulted an endocrinologist, who diagnosed him with gynecomastia. (Id. at 6-7; PMC Tr. 6:22-6:25). Radiological imaging confirmed the diagnosis in April 2024. (PMC Tr. 6:24-7:1; see also AC 7). Mr. Cummings’s libido still has not returned. (AC 7; PMC Tr. 21:9-21:21). In the process of being treated for gynecomastia, Mr. Cummings was repeatedly asked if he had been on any medications in the past, which caused him to look further into Zoloft’s side effects. (PMC Tr. 24:19-25:2). At that

point, Mr. Cummings realized a possible connection between taking Zoloft and the health issues he was experiencing. (Id.; see also AC 7). In fact, he asserts that Zoloft’s medication guide listed gynecomastia and hyperprolactinemia as possible side effects. (PMC Tr. 46:7-46:12). Mr. Cummings alleges that Mr. Cassar and Ms.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Selevan v. New York Thruway Authority
584 F.3d 82 (Second Circuit, 2009)
Coppedge v. United States
369 U.S. 438 (Supreme Court, 1962)
United Mine Workers of America v. Gibbs
383 U.S. 715 (Supreme Court, 1966)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
City of Revere v. Massachusetts General Hospital
463 U.S. 239 (Supreme Court, 1983)
Carnegie-Mellon University v. Cohill
484 U.S. 343 (Supreme Court, 1988)
Washington v. Harper
494 U.S. 210 (Supreme Court, 1990)
Rotella v. Wood
528 U.S. 549 (Supreme Court, 2000)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Jones v. Bock
549 U.S. 199 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
DiFolco v. MSNBC Cable L.L.C.
622 F.3d 104 (Second Circuit, 2010)
Faber v. Metropolitan Life Insurance
648 F.3d 98 (Second Circuit, 2011)
Bryant v. Wright
451 F. App'x 12 (Second Circuit, 2011)
Chance v. Armstrong
143 F.3d 698 (Second Circuit, 1998)
Kronisch v. United States
150 F.3d 112 (Second Circuit, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
Najay Cummings v. James Cassar, In Individual and Official Capacity, and Chelsea Whittaker, Counsel Stack Legal Research, https://law.counselstack.com/opinion/najay-cummings-v-james-cassar-in-individual-and-official-capacity-and-nysd-2025.